News

Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy ...

Cardiovascular Systems Inc. received the CE Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from...

Food and Drug Administration gave 510(k) clearance for the HawkOne directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system...

Cardiovascular Systems Inc. announced that the first seven patients in Japan have been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in the United States...

The first large prospective study to examine the effectiveness of laser atherectomy in the treatment of femoropopliteal in-stent restenosis (ISR) found that the procedure combined with...

Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online in the ...

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online today in the...

Cardiovascular Systems is recalling certain lots of the Diamondback 360 Peripheral Orbital Atherectomy System, because they may contain defective saline sheaths that could fracture during use. If...

July 18, 2014 — Avinger announced that John Pigott, M.D., of Jobst Vascular Institute, Toledo, Ohio, enrolled the first patient in the VISION trial, a global investigational device exemption (IDE...

Cardiovascular Systems Inc. (CSI) announced that the first patient has been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) trial.

June 9, 2014 — After one year, patients treated with orbital atherectomy, a procedure to sand away calcium in the coronary arteries prior to stenting, were less likely to require a repeat...

May 16, 2014 — In a move to expand significantly its portfolio of solutions for peripheral interventions, Boston Scientific Corp. has entered into a definitive agreement to acquire the...

Late-Breaking Trials SCAI May 2014

The Society for Cardiovascular Angiography and Interventions (SCAI) announced the late-breaking clinic al trial data presentations for it its upcoming 2014 Scientific Sessions, May 28-31, in Las...

Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH)...

The U.S. Food and Drug Administration (FDA) cleared Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial...

Spectranetics Excite ISR Atherectomy Systems Cath Lab Clinical Trial Study

The Spectranetics Corp. announced that the Excite ISR trial achieved the statistical endpoints of the adjunct analysis...

AngioDynamics AngioVac Atherectomy Systems Cath Lab Thrombectomy Devices

Instead of making a chest incision for open heart surgery, cardiovascular surgeons can now use a new vacuum-like tool to remove potentially deadly, large clots that lodge in patients’ hearts....

AtheroMed Phoenix Atherectomy System Device Peripheral Artery Disease PAD

AtheroMed, a developer of catheter technologies for treating ...

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 offers many new insights about the latest cardiovascular technologies and treatment techniques. These...

diamondback 360 mount sinai cath lab atherectomy

Interventional cardiologists at Mount Sinai Hospital are the first in the world to use a newly U.S. Food and Drug Administration (FDA)-approved device for the treatment of severely calcified...